Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for THLD
0.479
+0.032 (7.17%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.43 - 0.48
52 week 0.21 - 5.28
Open 0.46
Vol / Avg. 571,228.00/714,500.00
Mkt cap 36.75M
P/E 0.94
Div/yield     -
EPS 0.51
Shares 71.51M
Beta 3.85
Inst. own 43%
Jul 28, 2016
Q2 2016 Threshold Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 5, 2016
Q1 2016 Threshold Pharmaceuticals Inc Earnings Release
Mar 10, 2016
Q4 2015 Threshold Pharmaceuticals Inc Earnings Release
Mar 8, 2016
Threshold Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - 56.97%
Operating margin - 35.01%
EBITD margin - 36.31%
Return on average assets -66.50% 71.80%
Return on average equity -84.30% 519.53%
Employees 26 -
CDP Score - -

Address

Suite 300, 170 Harbor Way
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-4748200 (Phone)
+1-650-4742529 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Officers and directors

Harold E. Selick Ph.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Stewart M. Kroll Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 45
Bio & Compensation  - Reuters
Mark Hopkins J.D., Ph.D., Vice President - Intellectual Property and Assistant General Counsel
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Jeffrey W. Bird Independent Director
Age: 54
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 51
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 70
Bio & Compensation  - Reuters
Wilfred E. Jaeger M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
George G. C. Parker Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters